Usana Health Sciences Narrows FY2024 GAAP EPS Guidance from $2.40-2.55 to $2.45 vs $2.50 Est; Narrows FY2024 Sales Guidance from $850.00M-880.00M to $850.00M vs $861.94M Est.
Portfolio Pulse from Benzinga Newsdesk
Usana Health Sciences has revised its FY2024 guidance, narrowing its GAAP EPS to $2.45, slightly below the $2.50 analyst estimate, and its sales outlook to $850 million, below the $861.94 million estimate.
October 22, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Usana Health Sciences has adjusted its FY2024 guidance, with GAAP EPS now at $2.45, slightly below the analyst estimate of $2.50, and sales guidance at $850 million, below the $861.94 million estimate.
The narrowing of both EPS and sales guidance to figures below analyst estimates suggests potential challenges in meeting market expectations, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100